YUCAIPA, Calif., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the company is an exhibitor at the American Association of Respiratory Care (AARC) 55th international respiratory congress in San Antonio-Texas next month, Further, CEO, Scott Sand, will discuss the AARC exhibition tomorrow November 17, 2009 at 11:34AM eastern standard time on The Money Channel's American Scene Radio with host Steve Crowley.
Since 1947, the American Association for Respiratory Care (AARC) has been committed to enhancing professionalism as a respiratory care practitioner, improving performance on the job, and helping to broaden the scope of knowledge essential to the clinician's success. With more than 47,000 members nationwide, the AARC is the only professional society for respiratory therapists in hospitals and with home care companies, managers of respiratory and cardiopulmonary services, and educators who provide respiratory care training.
The company is an exhibitor at this year's 55th International Congress of the American Association of Respiratory Care held in San Antonio, Texas from December 5th through December 7th, 2009. The company will show-case the new Oxyview Nasal Cannula in a priority corner booth no. 381. "This is a very important exhibit for Ingen to attend to introduce the new Oxyview Nasal Cannula to the respiratory therapists and hospitals worldwide. Our marketing staff attending will give away more than 2000 samples of our products to the other exhibitors and attendees, as well as a newly designed 2 page product brochure, several thousand issues of the new Medco Forum Oxyview publication and the most recently published COPD Digest with the Oxyview Nasal Cannula ad on the back cover," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
http://www.moneychannel.tv/scas.php
About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufacturers all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.